Evidence map›Paper›PMID 31515710›Full record

ArticleDrugs & aging2019

Patients' Attitudes Towards Deprescribing Alpha-Blockers and Their Willingness to Participate in a Discontinuation Trial.

Malou Edelman, Petra Jellema, Eelko Hak, Petra Denig, Marco H Blanker

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drugs & aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Consumer Attitudes Towards Deprescribing: A Systematic Review and Meta-Analysis.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Malou EdelmanDepartment of General Practice and Elderly Medicine, University Medical Centre Groningen, University of Groningen, Huispostcode FA21, P.O. Box 196, 9700 AD, Groningen, The Netherlands.
Petra JellemaDepartment of General Practice and Elderly Medicine, University Medical Centre Groningen, University of Groningen, Huispostcode FA21, P.O. Box 196, 9700 AD, Groningen, The Netherlands.
Eelko HakUnit of Pharmaco-Therapy Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.
Petra DenigClinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.
Marco H BlankerDepartment of General Practice and Elderly Medicine, University Medical Centre Groningen, University of Groningen, Huispostcode FA21, P.O. Box 196, 9700 AD, Groningen, The Netherlands. m.h.blanker@umcg.nl.ORCID http://orcid.org/0000-0002-1086-8730
University Medical Center Groningen · NLUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe objective of this study was to gain insights into the attitudes of men with lower urinary tract symptoms towards deprescribing alpha-blockers and to assess their willingness to participate in a planned discontinuation trial.

methodsThis was a cross-sectional questionnaire study. Men aged 30 years and older with lower urinary tract symptoms, who were first prescribed an alpha-blocker in 2015 or 2016, were selected from a population-based prescription database. We recorded lower urinary tract symptom severity (e.g., International Prostate Symptom Score and Overactive Bladder questionnaire) and patient characteristics (e.g., comorbidity and polypharmacy). The linguistically validated Dutch version of the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire was also used, to which we added ten specific questions on attitudes towards the deprescribing of alpha-blockers. Information about a future discontinuation trial on alpha-blockers was then provided and participants were asked to indicate if they would participate. We explored the explanatory factors for the willingness to participate by logistic regression analyses.

resultsOf the 1380 patients in the database, 421 were using an alpha-blocker, and 195 completed the questionnaire. Of these, 16 men were excluded because of indwelling catheter use or unknown indication. The mean age of the 179 participants was 69.4 (standard deviation 9.2) years. Most men were satisfied with their current therapy, but almost all (93%) were willing to stop the medicine at the request of a doctor. Therefore, most men (61%) were willing to participate in the proposed alpha-blocker discontinuation trial. Willingness to stop therapy was affected by patients' perceptions of the appropriateness of alpha-blocker therapy and concerns about stopping that therapy.

conclusionsAlthough men who use alpha-blockers are generally satisfied with their current therapy, most will participate in a discontinuation trial.

Indexed as

DeprescriptionsAdrenergic alpha-AntagonistsAgedAttitudeCross-Sectional StudiesHumansLower Urinary Tract SymptomsMaleMiddle AgedPatient Acceptance of Health CarePolypharmacySurveys and QuestionnairesAdrenergic alpha-Antagonists

Identifiers

PMID31515710
PMCPMC6884428
OpenAlexW2982594147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.